The 6-monthly MS treatment refers to OCREVUS, an intravenous (IV) infusion medication.
Understanding OCREVUS for Multiple Sclerosis
OCREVUS is a disease-modifying therapy (DMT) that is approved by the FDA for both relapsing and primary progressive forms of multiple sclerosis (MS). It works by targeting specific immune cells, known as CD20-positive B cells, which play a key role in the progression of the disease. This targeted approach helps to reduce inflammation and the frequency of relapses.
How OCREVUS is Administered
OCREVUS is administered through an intravenous infusion, typically taking a few hours. The schedule for treatment is:
- Initial Doses: The first dose is split into two infusions, given two weeks apart.
- Maintenance Doses: Following the initial doses, OCREVUS is administered once every six months.
Key Features of OCREVUS
| Feature | Description |
|---|---|
| Target | CD20-positive B cells |
| Route of Admin | Intravenous (IV) Infusion |
| Frequency | Once every six months, following initial doses |
| Approved For | Relapsing and primary progressive MS |
| Mechanism | Reduces the activity of the CD20-positive B cells, which contributes to the immune attacks on the brain and spinal cord in MS. |
Practical Insights
- Infusion Center: You'll need to go to an infusion center or clinic for each OCREVUS treatment.
- Pre-Medication: Doctors typically give a pre-medication to minimize infusion reactions.
- Monitoring: While receiving treatment, patients are typically monitored for any potential side effects.
- Treatment Plan: A personalized treatment plan, including details about dosing and schedules, is determined by the prescribing physician.
OCREVUS stands out as a convenient option for some patients due to its twice-yearly administration.
